Cytek Biosciences Narrows FY25 Revenue Guidance to $196M-$200M

Cytek Biosciences has narrowed its FY25 revenue guidance to $196M-$200M from $196M-$210M. The company expects full-year 2025 revenue to grow by -2% to +2% over 2024, assuming no change in currency exchange rates. This guidance is slightly lower than the consensus estimate of $197.94M.

Cytek Biosciences (Nasdaq: CTKB) has adjusted its full-year 2025 revenue guidance to a range of $196 million to $205 million, a slight reduction from its previous estimate of $196 million to $210 million. This revised outlook reflects a projected growth rate of -2% to +2% over 2024, assuming no change in currency exchange rates. The new guidance is slightly lower than the consensus estimate of $197.94 million [1].

The company's Q2 2025 financial results showed mixed performance. Total revenue for the quarter was $45.6 million, a 2% decrease from Q2 2024, primarily due to weakened product sales in EMEA and APAC regions. However, the company expanded its installed base to 3,295 instruments, adding 146 units in Q2 2025, and saw a 16% growth in recurring revenue, which now constitutes 32% of trailing twelve-month revenue. The launch of the Cytek Aurora™ Evo system, with enhanced capabilities like faster throughput and automated functions, was a strategic move to bolster its competitive position [1].

Despite these mixed results, Cytek Biosciences remains focused on expanding its installed base globally and growing its recurring revenue through service and reagent businesses. The company's cash position remained strong at $262.0 million, with a slight decrease from the previous quarter due to a $4.5 million share repurchase [1].

The revised revenue guidance reflects continued market headwinds but also Cytek Biosciences' commitment to building a more durable business model. The company plans to continue strengthening its market leadership through innovation and expects the instrument market to recover over time. Cytek Biosciences will host a conference call on August 6, 2025, at 1:30 p.m. Pacific Time/4:30 p.m. Eastern Time to discuss its second quarter 2025 financial results [1].

References:
[1] https://www.stocktitan.net/news/CTKB/cytek-biosciences-reports-second-quarter-2025-financial-z204onsvzzjf.html